3 results
Approved WMOCompleted
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
Approved WMOCompleted
To assess indacaterol (300 and 600 ug once daily via SDDPI) superiority in patients with COPD as compared to placebo with respect to 24 h post dose (through) FEV1 after 12 weeks of treatment.
Approved WMOCompleted
The primary objective of this study is to investigate the effects of classical conditioning with intranasal insulin on endogenous insulin and glucose levels in diabetes type-2 patients and healthy controls. Additionally, we will examine the effects…